Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233436 · ClinicalTrials.gov registry record · Phase 1
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05233436 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 21 participants.
The verdict
NCT05233436, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the recommended dose of PF-07265028 monotherapy and in combination for potential further studies and development. The study contains 2 parts, Dose Escalation (Part 1) to determine the recommended dose of PF-07265028 as single agent and in combination, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose. It is expected that most participants will take part in this study for up to 1 year with six on-site visits in the first month and then at least twice every subsequent month while they are on treatment.
Interventions
- DRUG PF-07265028
- BIOLOGICAL Sasanlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-02-24 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05233436
The ClinicalTrials.gov registry entry for NCT05233436 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-07265028 is the first listed.
NCT05233436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05233436 about?
NCT05233436 is a clinical study titled "PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors". The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the re...
What is the current status of trial NCT05233436?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-02-24. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT05233436?
The interventions under investigation include: PF-07265028 (DRUG), Sasanlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05233436?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.